期刊文献+

三阴性乳腺癌的临床病理特征分析 被引量:1

Analysis of clinicopathological features in triple negative breast cancer
下载PDF
导出
摘要 目的:探讨三阴性乳腺癌(triple negative breast cancer,TNBC)的临床病理特点,以及TNBC中突变型p53的表达及其意义。方法:回顾性分析195例乳腺癌病例,按雌激素受体、孕激素受体、人表皮生长因子受体2的表达分为TNBC组34例和对照组161例。检测TNBC组织中突变型p53的表达,分析其与TNBC临床病理特征及预后的关系。结果:TNBC组病人的复发转移率较高(29.4%比1.2%,P<0.001)、无病生存率显著低于对照组(52.9%比90.7%,P<0.001)。TNBC组突变型p53阳性表达率明显高于对照组(47.1%比22.4%,P<0.01),且突变型p53阳性表达与TNBC腋窝淋巴结转移有关(77.8%比36.0%,P<0.05)。结论:TNBC乳腺癌复发转移率高,无病生存率较低,预后较差。TNBC组织中突变型p53表达上调,其可作为TNBC重要的预后指标。 Objective To investigate the clinicopathological features and the expression of mutated p53 protein in the patients with triple negative breast cancer(TNBC). Methods There were 195 cases studied retrospectively including 34 cases in TNBC group and 161 cases in control group(non-TNBC) by the tests of expression of estrogen receptor and progesterone receptor and human epidermal growth factor receptor-2. The expression of mutated p53 protein was also detected. Results The higher both recurrence and metastasis and shorter time of disease free survival of the patients in TNBC group were found compared with those in control group (29.4% vs 1.2%, P〈0.001). The rate of the patients with desease free survival in TNBC group was less than that in control group (52.9% vs 90.7%, P〈0.001). The patients with the expression of mutated p53 protein in TNBC group was more than that in control group (47.1% vs 22.4%, P〈0.01). Conclusions The patients with TNBC may have poor prognosis. Expression of mutated p53 in TNBC could be regarded as an important biomarker for prognosis.
出处 《外科理论与实践》 2014年第2期136-139,共4页 Journal of Surgery Concepts & Practice
关键词 三阴性乳腺癌 临床病理特征 P53蛋白 预后 Triple negative breast cancer Clinicopathological feature p53 protein Prognosis
  • 相关文献

参考文献18

  • 1Rakha EA, Ellis IO. Triple negative/basal-like breast cancer:review[J]. Pathology, 2009,41(1):40-47.
  • 2Rastelli F, Bianeanelli S, Falzetta A, et at Triple negative breast cancer:currentstateofthear: Tumori,2010,96(6):875-88&.
  • 3李荣晖,杜彩文,张国君.三阴性乳腺癌的靶向治疗研究进展[J].国际肿瘤学杂志,2012,39(7):519-522. 被引量:3
  • 4Rana RN. A retrospective review of demographics and stage of triple-negative breast cancer[J]. J Clin Oncol, 2009,27 ( 15 ) :el 1553.
  • 5Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients:a single-institu- tion compilation compared with the National Cancer Insti- tute's Surveillance,Epidemiology, and End Results database[J]. Cancer, 2007,110(4) : 876-884.
  • 6Kurebayashi J, Moriya T, Ishida T, et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races[J]. Breast, 2007,16(Suppl 2): S72-S77.
  • 7Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic signi- ficance of the basal-like subtype of breast cancer:a com- parison with hormone receptor and Her2/neu-overex- pressing phenotype[J]. Hum Pathol,2006,37(9):1217-1226.
  • 8Yin WJ, Lu JS, Di GH, et al. Clinicopathological features of the triple-negative tumors in Chinese breast cancer pa- tients[J]. Breast Cancer Res Treat, 2009,115(2):325-333.
  • 9Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms [J]. BMC Genomics,2006,7(7):96-107.
  • 10Perou CM, Sorlie T, Eisen MB, et al. Molecularportraits of human breast tumors[J]. Nature, 2000,406(6797) : 747-752.

二级参考文献52

  • 1Perou CM,Sorlie T,Eisen Mb,et al.Molecularportraits of humanbreast tumors[J].Nature,2000,406(6797):747-752.
  • 2Cheang MC,Voduc D,Bajdik C,et al.Basal like breast cancer de-fined by five bio markers has superior prognostic value than triplenegative phenotype[J].Clin Cancer Res,2008,14(5):1368-1376.
  • 3Gerson R,Alban F,Villalobos A,et al.Recurrence and survivalrates among early breast cancer cases with triple negative immuno-phenotype[J].Gac Med Mex,2008,144(1):27-34.
  • 4Mise M,Higashide S,Hashimoto K,et al.Clinicopathological fea-tures of young patients with triple negative breast cancer[J].GanTo Kagaku Ryoho,2009,36(10):1677-1681.
  • 5Mersin H,Yildirim E,Berberoglu U,et al.The prognostic impor-tance of triple negative breast carcinoma[J].Breast,2008,17(4):341-346.
  • 6Rhee J,Han SW,Oh DY,et al.The clinicopathologic characteris-tics and prognostic significance of triple-negativity in node-negativebreast cancer[J].BMC Cancer,2008,8(3):307.
  • 7Dent R,Trudeau M,Pritchard KI,et al.Triple-negative breastcancer:clinical features and patterns of recurrence[J].Clin CancerRes,2007,13(15):4429-4434.
  • 8Young SR,Pilarski RT,Donenberg T,et al.The prevalence of BRCA1 mutations among young women with triple negative breastcancer[J].BMC Cancer,2009,9(4):86.
  • 9Daniel PS,Andrea L,Richardson AC,et al.Efficacy of neoadju-vant cisplatin in triple-negative breast cancer[J].Clin Oncol,2010,28(7):1145-1153.
  • 10DentR, TrudeanM, Pritchard KI, et al. Triple-negative breast can eers: clinical features and patterns of recurrence. Clin Cancer Res, 2007, 13 ( 15 ) :4429-4434.

共引文献12

同被引文献15

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部